| (210) | Number of the EPO application | 23716356 |
| (220) | Filing date of the EPO application | 2023.03.06 |
| (80) | EPO patent specification publication (B) | EPB nr. 04/2026, 2026.01.21 |
| (110) | EPO patent number | 4489730 |
| (21) | Number of the application | e 2025 0082 |
| (71) | Name(s) of applicant(s), code of the country | Janssen Pharmaceuticals, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | GOYVAERTS Nicolaas Martha Felix, BE;
SCHMIDT Mark, BE;
POPOVA Vanina, BE;
SAVITZ Adam J., US;
MELKOTE Rama, US;
DREVETS Wayne C., US;
GOPAL MD Srihari, US;
PEMBERTON Darrel, BE;
LAGISHETTY Chakradhar, US;
KEZIC Iva, BE;
SAMTANI Mahesh N., US;
HUYBRECHTS Tom, BE;
VAN DER AVOORT Geert, BE;
RAVELINGIEN Matthieu, BE;
MARCOS Laura Martinez, BE;
MARCOZZI Tatiana, BE;
JOKICEVIC Katarina, BE; |
| (73) | Name(s) of owner(s), code of the country | JANSSEN Pharmaceuticals Inc., US; |
| (54) | Title of the invention | COMPOSITIONS COMPRISING ATICAPRANT |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 9/20 (2006.01.01); A61K 31/40 (2006.01.01); A61P 25/24 (2006.01.01) |
| (52) | Cooperative Patent Classification | A61K 31/40 (EP); A61K 9/2018 (EP); A61K 9/2054 (EP); A61P 25/24 (EP) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2025.02.28 |
| (30) | Priority | 202263317471 P, 2022.03.07, US |
| (86) | International application | PCT/IB2023/052097, 2023.03.06 |
| (87) | International publication | WO 2023/170554, 2023.09.14 |